Loxo Oncology, Inc. (NASDAQ:LOXO) shares moved down -1.28% in last trading session and ended the day at $32.52. LOXO has a return on assets of -28.50%. Loxo Oncology, Inc. (NASDAQ:LOXO) quarterly performance is 58.33%.
On 17 November, Loxo Oncology, Inc. (NASDAQ:LOXO), announced the closing of its previously announced underwritten public offering of 2,875,000 shares of common stock at a public offering price of $26.50 per share, which included the exercise in full by the underwriters of their option to purchase 375,000 additional shares of common stock to cover over-allotments.
Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB) ended the last trading day at $68.81. Company weekly volatility is calculated as 3.28% and price to cash ratio as 43.97. Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB) showed a weekly performance of 3.93%.
Red Robin Gourmet Burgers, Inc. (NASDAQ:RRGB) is two weeks away from bringing craveable gourmet burgers to Tualatin, Ore. Located at 7425 SW Nyberg St., at the Nyberg Rivers Shopping Center in front of Cabela’s and LA Fitness, the newest Red Robin® restaurant will open on December 7 at 11 a.m.
On 25 November, Heska Corporation (NASDAQ:HSKA) shares advanced 3.27% and was closed at $34.39. HSKA EPS growth in last 5 year was -0.90%. Heska Corporation (NASDAQ:HSKA) year to date (YTD) performance is 89.69%.
On November 19, 2015, the Board of Directors of Heska Corporation (NASDAQ:HSKA) determined John McMahon, age 50, would serve as the Company’s principal accounting officer. Mr. McMahon joined the Company on October 14, 2015, and will continue to receive an annual base salary of $230,000 pursuant to his existing employment agreement with the Company dated October 14, 2015.
Sophiris Bio, Inc. (NASDAQ:SPHS) shares advanced 5.94% in last trading session and ended the day at $2.14. SPHS has a return on assets of -94.20%. Sophiris Bio, Inc. (NASDAQ:SPHS) quarterly performance is 148.84%.
On 16 November, Sophiris Bio, Inc. (NASDAQ:SPHS) reported a net loss of $3.7 million ($0.22 per share) for the three months ended September 30, 2015 compared to a net loss of $8.2 million ($0.49 per share) for the three months ended September 30, 2014.
Albany Molecular Research Inc. (NASDAQ:AMRI) caters to the Healthcare space. It has a net profit margin of -1.70% and weekly performance is -0.89%. On the last day of trading company shares ended up at $20.00. Albany Molecular Research Inc. (NASDAQ:AMRI) distance from 50-day simple moving average (SMA50) is -5.88%.
Albany Molecular Research Inc. (NASDAQ:AMRI) announced that William S. Marth, AMRI’s President and Chief Executive Officer, presented at the Jefferies Autumn 2015 Global Healthcare Conference London on Wednesday, November 18, 2015 at 5:20 p.m. GMT.
Leave a Reply